- Home
- GYRE vs NGL Comparison
GYRE vs NGL Comparison
Compare GYRE & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NGL
- Stock Information
- Founded
- GYRE 2002
- NGL 1940
- Country
- GYRE United States
- NGL United States
- Employees
- GYRE N/A
- NGL N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NGL Natural Gas Distribution
- Sector
- GYRE Health Care
- NGL Utilities
- Exchange
- GYRE Nasdaq
- NGL Nasdaq
- Market Cap
- GYRE 897.1M
- NGL 751.7M
- IPO Year
- GYRE N/A
- NGL 2011
- Fundamental
- Price
- GYRE $7.28
- NGL $6.13
- Analyst Decision
- GYRE Strong Buy
- NGL
- Analyst Count
- GYRE 1
- NGL 0
- Target Price
- GYRE $18.00
- NGL N/A
- AVG Volume (30 Days)
- GYRE 92.0K
- NGL 489.4K
- Earning Date
- GYRE 11-12-2025
- NGL 11-11-2025
- Dividend Yield
- GYRE N/A
- NGL N/A
- EPS Growth
- GYRE N/A
- NGL N/A
- EPS
- GYRE 0.02
- NGL N/A
- Revenue
- GYRE $102,189,000.00
- NGL $3,332,108,000.00
- Revenue This Year
- GYRE $16.80
- NGL N/A
- Revenue Next Year
- GYRE $50.29
- NGL N/A
- P/E Ratio
- GYRE $428.23
- NGL N/A
- Revenue Growth
- GYRE N/A
- NGL 1.08
- 52 Week Low
- GYRE $6.11
- NGL $2.64
- 52 Week High
- GYRE $19.00
- NGL $7.15
- Technical
- Relative Strength Index (RSI)
- GYRE 44.66
- NGL 57.82
- Support Level
- GYRE $7.20
- NGL $5.80
- Resistance Level
- GYRE $7.72
- NGL $6.13
- Average True Range (ATR)
- GYRE 0.28
- NGL 0.24
- MACD
- GYRE -0.01
- NGL -0.10
- Stochastic Oscillator
- GYRE 28.58
- NGL 22.59
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.